Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients
Status:
Unknown status
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Sirolimus (Rapamune) in improving
the function of the transplant kidney, without any increase in the risk of acute rejection or
adverse side effects, compared with Tacrolimus (Prograf).
We hypothesize that Sirolimus, as one component of a long-term steroid-free immunosuppressive
regimen, will be effective in maintaining a low incidence of acute rejection and a short- and
long-term graft survival comparable to Tacrolimus with better graft function in the high-risk
African-American renal transplant population with immediate graft function.